Appearance of anti-acetylcholine receptor antibodies after COVID-19

Autores/as

  • Pedro Helder de Oliveira Junior Universidade Federal do Ceará (UFC), Fortaleza, Ceará, Brasil
  • Walisson Grangeiro Bringel Silva Universidade Federal do Ceará (UFC), Fortaleza, Ceará, Brasil
  • Hermany Capistrano Freitas Hospital Geral de Fortaleza (HGF), Fortaleza, Ceará, Brasil
  • Cleonísio Leite Rodrigues Hospital Geral de Fortaleza (HGF), Fortaleza, Ceará, Brasil
  • Paulo Ribeiro Nóbrega Universidade Federal do Ceará (UFC), Fortaleza, Ceará, Brasil

DOI:

https://doi.org/10.20513/2447-6595.2025v65n1e90635

Palabras clave:

Myasthenia Gravis, COVID-19, SARS-CoV-2

Resumen

Objectives: In this paper, we report a case of Myasthenia Gravis (MG) exacerbated by COVID-19 that was initially anti-acetylcholine receptor (AChR) negative and after 9 months became positive for anti-AChR antibodies. Methods: We performed a review of the medical records and clinical follow-up of a patient followed at the Neurology service of Walter Cantídio University Hospital. Results: A 37-year-old female patient presented with mild dysphonia, ptosis and diplopia. Three months later, she was admitted to the hospital with respiratory failure associated with COVID-19. The patient received a clinical diagnosis of MG and anti-AChR and MuSK antibodies were negative at that moment. Nine months after initial presentation, serum anti-AChR antibodies were positive. Conclusion: We reported a patient who presented seroconversion for anti-AChR antibodies after COVID-19. There have been some reports of possible viral triggers for myasthenia, but controversy over this matter still remains.

Descargas

Los datos de descargas todavía no están disponibles.

Publicado

2025-05-02

Número

Sección

RELATOS DE CASO